Litcius/Paper detail

Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

Bernadett Szabados, Mark Kockx, Zoe J. Assaf, Pieter‐Jan van Dam, Alejo Rodríguez‐Vida, Ignacio Durán, Simon J. Crabb, Michiel S. van der Heijden, Albert Font Pous, Gwénaëlle Gravis, Urbano Anido Herranz, Andrew Protheroe, Alain Ravaud, Denis Maillet, María José Méndez, Cristina Suárez, Mark Linch, Aaron Prendergast, Charlotte Tyson, Diana Stanoeva, Sofie Daelemans, Miche Rombouts, Sanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Shruti Sharma, Alexey Aleshin, Romain Banchereau, Daniel Castellano, Thomas Powles

2022European Urology190 citationsDOIOpen Access PDF

Topics & Concepts

MedicineBladder cancerCystectomyAtezolizumabHazard ratioInternal medicineOncologyUrologyNeoadjuvant therapyCisplatinConfidence intervalChemotherapyCancerBreast cancerPembrolizumabImmunotherapyBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersEsophageal Cancer Research and Treatment
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder | Litcius